column column
Health

Moderna, Merck cancer vaccine posts promising late-stage trial results

DS Staff | Aug 20, 2026

Merck and Moderna’s experimental personalized cancer vaccine has achieved a key goal in a late-stage melanoma trial, strengthening its prospects as a future treatment.